These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27021197)

  • 21. Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
    Younossi ZM; Stepanova M; Gordon S; Zeuzem S; Mann MP; Jacobson I; Bourliere M; Cooper C; Flamm S; Reddy KR; Kowdley K; Younossi I; Hunt S
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):567-574.e6. PubMed ID: 29155352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
    Fagundes RN; Ferreira LEVVC; Pace FHL
    PLoS One; 2020; 15(8):e0237005. PubMed ID: 32813740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
    Younossi ZM; Stepanova M; Afdhal N; Kowdley KV; Zeuzem S; Henry L; Hunt SL; Marcellin P
    J Hepatol; 2015 Aug; 63(2):337-45. PubMed ID: 25795586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
    Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
    Elfeki MA; Abou Mrad R; Modaresi Esfeh J; Zein NN; Eghtesad B; Zervos X; Hanouneh IA; O'Shea R; Carey WD; Alkhouri N
    Transplantation; 2017 May; 101(5):996-1000. PubMed ID: 27631598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes.
    Cacoub P; Bourliere M; Asselah T; De Ledinghen V; Mathurin P; Hézode C; Henry L; Stepanova M; Younossi ZM
    Value Health; 2018 Oct; 21(10):1218-1225. PubMed ID: 30314623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.
    Scheiner B; Schwabl P; Steiner S; Bucsics T; Chromy D; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Peck-Radosavljevic M; Reiberger T; Mandorfer M
    Medicine (Baltimore); 2016 Jul; 95(27):e4061. PubMed ID: 27399090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
    Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
    Liu CH; Su TH; Liu CJ; Hong CM; Yang HC; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1620-1625. PubMed ID: 30693965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C.
    de Avila L; Weinstein AA; Estep JM; Curry MP; Golabi P; Escheik C; Birerdinc A; Stepanova M; Gerber L; Younossi ZM
    Liver Int; 2019 Sep; 39(9):1631-1640. PubMed ID: 30959554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.
    He QF; Zhang QF; Zhang DZ
    Dig Dis Sci; 2016 Nov; 61(11):3108-3117. PubMed ID: 27619394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
    Younossi ZM; Elsheikh E; Stepanova M; Gerber L; Nader F; Stamm LM; Brainard DM; McHutchinson JG
    J Viral Hepat; 2015 Dec; 22(12):977-82. PubMed ID: 26280786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
    Younossi ZM; Stepanova M; Jacobson IM; Asselah T; Gane EJ; Lawitz E; Foster GR; Roberts SK; Thompson AJ; Willems BE; Welzel TM; Pearlman B; Younossi I; Racila A; Henry L
    Aliment Pharmacol Ther; 2018 Jan; 47(2):259-267. PubMed ID: 29181842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
    Gerber L; Estep M; Stepanova M; Escheik C; Weinstein A; Younossi ZM
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):156-64.e3. PubMed ID: 26241510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
    Younossi ZM; Stepanova M; Feld J; Zeuzem S; Jacobson I; Agarwal K; Hezode C; Nader F; Henry L; Hunt S
    J Hepatol; 2016 Jul; 65(1):33-39. PubMed ID: 26956698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
    Shiha G; Esmat G; Hassany M; Soliman R; Elbasiony M; Fouad R; Elsharkawy A; Hammad R; Abdel-Razek W; Zakareya T; Kersey K; Massetto B; Osinusi A; Lu S; Brainard DM; McHutchison JG; Waked I; Doss W
    Gut; 2019 Apr; 68(4):721-728. PubMed ID: 29666174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
    Thu Thuy PT; Bunchorntavakul C; Tan Dat H; Palecki J; Reddy KR
    Antivir Ther; 2018; 23(5):415-423. PubMed ID: 29303482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
    Flisiak R; Łucejko M; Mazur W; Janczewska E; Berak H; Tomasiewicz K; Mozer-Lisewska I; Kozielewicz D; Gietka A; Sikorska K; Wawrzynowicz-Syczewska M; Nowak K; Zarębska-Michaluk D; Musialik J; Simon K; Garlicki A; Pleśniak R; Baka-Ćwierz B; Olszok I; Augustyniak K; Stolarz W; Białkowska J; Badurek A; Piekarska A
    Adv Med Sci; 2017 Sep; 62(2):387-392. PubMed ID: 28554119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.